Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III ART-123 for acute exacerbation of idiopathic pulmonary fibrosis
jRCT2080223271Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing ART-123 + steroids with Placebo + steroids (2 arms). Started Jul 2016; status: completed.
02
Drugs
thrombomodulin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2080223271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223271.